Despite the key evidence on the oncosuppressive role of RNASET2 described above, endogenous RNASET2 expression (when evaluated at the mRNA level) in ovarian cancer cell lines and/or primary tumor was long established to vary in a wide range, from RNASET2-null to high-expressing levels. This evidence concerns the gene RNASET2 and ovarian cancer.